S2-E30.3 - The Global Liver institute US NASH Action Plan - treatment and health system challenges

Send us a text

Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI's US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group considers systems issues ranging from commitment to multi-disciplinary approaches to including Fatty Liver metrics in metrics like HEDIS in terms of their ability to focus needed care and attention on NAFLD and NASH.

Michael Fuchs starts by discussing the value of having a multi-disciplinary mission and vision for patient treatment. From there, the group points to several different approaches -- communication, metrics, education -- that will be pivotal to driving that kind of vision and making it effective. In the end, the panelists discuss actions they each can take over the next six months to move us closer to realizing the Action Plan vision.

This conversation is sponsored with a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.